Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2022-01-04 00:00:00 ET · period of report 2021-12-30 · accession 0001567619-22-000389 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-04 | 2021-12-30 | ARQT | Burnett Patrick | See Remarks | A - Grant | $0.00 | +16.8K | 26.2K | +176% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-30 | A | A | 16,750 | $0.00 | 26,250 | D | — | — | (F1) On August 3, 2020, the Reporting Person was granted performance-based restricted stock units ("RSUs") subject to a milestone condition. The Compensation Committee of the Issuer certified the achievement of the milestone and commencement of vesting on December 30, 2021 (the "Milestone Vesting Commencement Date"). 25% of the performance-based RSUs shall vest annually from the Milestone Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. (F2) Includes 26,250 RSUs. |